Evidence map›Paper›PMID 32112426›Full record

ArticleAllergy2020

Butyrate inhibits human mast cell activation via epigenetic regulation of FcεRI-mediated signaling.

Jelle Folkerts, Frank Redegeld, Gert Folkerts, Bart Blokhuis, Mariska P M van den Berg, Marjolein J W de Bruijn, Wilfred F J van IJcken, Tobias Junt, See-Ying Tam, Stephen J Galli and 3 more

Open access · bronzeAbstract read
In one paragraph

Article in Allergy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 110 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
110citing papers in PubMed, 3 pooled it
6.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

110 citing papers in PubMed, 3 syntheses or guidelines pooled it, 162 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Butyrate SilencesAllergy, asthma & immunology research · 2026
    Article
  20. Review

50 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 4 countries.

Jelle FolkertsDivision of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands.ORCID 0000-0002-1014-330X
Frank RedegeldDivision of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands.
Gert FolkertsDivision of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands.
Bart BlokhuisDivision of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands.
Mariska P M van den BergDepartment of Molecular Pharmacology, Faculty of Science and Engineering, University of Groningen, Groningen, The Netherlands.
Marjolein J W de BruijnDepartment of Pulmonary Medicine, Erasmus MC Rotterdam, Rotterdam, The Netherlands.
Wilfred F J van IJckenCenter for Biomics, Erasmus MC Rotterdam, Rotterdam, The Netherlands.ORCID 0000-0002-0421-8301
Tobias JuntDepartment of Autoimmunity, Transplantation and Inflammation, Novartis Institutes for BioMedical Research, Basel, Switzerland.
See-Ying TamDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Stephen J GalliDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Rudi W HendriksDepartment of Pulmonary Medicine, Erasmus MC Rotterdam, Rotterdam, The Netherlands.
Ralph StadhoudersDepartment of Pulmonary Medicine, Erasmus MC Rotterdam, Rotterdam, The Netherlands.
Marcus MaurerDermatological Allergology, Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, Germany.ORCID 0000-0002-4121-481X
Erasmus MC · NLUtrecht University · NLStanford University · USCharité - Universitätsmedizin Berlin · DENovartis (Switzerland) · CHUniversity of Groningen · NL

Funding

Tracking allergen specific T cells in multi-food allergyU19AI104209 · NIAID · STANFORD UNIVERSITY · PI CHINTHRAJAH, R. SHARON · 2013 to 2025
$17.3M
Role of nociceptive sensory neuron/mast cell interactions in cutaneous allergic inflammationR01AI132494 · NIAID · STANFORD UNIVERSITY · PI GALLI, STEPHEN JOSEPH · 2017 to 2021
$2.4M
RabGEF1 in MyD88 signaling, skin immunity, and atopic dermatitisR01AR067145 · NIAMS · STANFORD UNIVERSITY · PI GALLI, STEPHEN JOSEPH · 2015 to 2019
$1.9M
NIAID NIH HHS R01 AI132494NIAID NIH HHS U19 AI104209NIAMS NIH HHS R01 AR067145NIH/NIAID R01 AI1324 94NIH/NIAID U19AI104 209
6 · The paper itself

Abstract

backgroundShort-chain fatty acids (SCFAs) are fermented dietary components that regulate immune responses, promote colonic health, and suppress mast cell-mediated diseases. However, the effects of SCFAs on human mast cell function, including the underlying mechanisms, remain unclear. Here, we investigated the effects of the SCFAs (acetate, propionate, and butyrate) on mast cell-mediated pathology and human mast cell activation, including the molecular mechanisms involved.

methodPrecision-cut lung slices (PCLS) of allergen-exposed guinea pigs were used to assess the effects of butyrate on allergic airway contraction. Human and mouse mast cells were co-cultured with SCFAs and assessed for degranulation after IgE- or non-IgE-mediated stimulation. The underlying mechanisms involved were investigated using knockout mice, small molecule inhibitors/agonists, and genomics assays.

resultsButyrate treatment inhibited allergen-induced histamine release and airway contraction in guinea pig PCLS. Propionate and butyrate, but not acetate, inhibited IgE- and non-IgE-mediated human or mouse mast cell degranulation in a concentration-dependent manner. Notably, these effects were independent of the stimulation of SCFA receptors GPR41, GPR43, or PPAR, but instead were associated with inhibition of histone deacetylases. Transcriptome analyses revealed butyrate-induced downregulation of the tyrosine kinases BTK, SYK, and LAT, critical transducers of FcεRI-mediated signals that are essential for mast cell activation. Epigenome analyses indicated that butyrate redistributed global histone acetylation in human mast cells, including significantly decreased acetylation at the BTK, SYK, and LAT promoter regions.

conclusionKnown health benefits of SCFAs in allergic disease can, at least in part, be explained by epigenetic suppression of human mast cell activation.

Indexed as

ButyratesMast CellsAnimalsCell DegranulationEpigenesis, GeneticGuinea PigsHumansMiceProtein-Tyrosine KinasesReceptors, IgEButyratesProtein-Tyrosine KinasesReceptors, IgEbutyrateFcεRI signalinghistone deacetylasemast cellsshort-chain fatty acids

Identifiers

PMID32112426
PMCPMC7703657
OpenAlexW3007237938

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.